Fisher And Paykel Healthcare Corpo stock
Price history
+26.67% over the period1 year: from $31.91 (November 20, 2025) to $40.42 (November 20, 2026), +26.67%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $40.42 |
| October 30, 2026 | $38.13 |
| September 30, 2026 | $37.43 |
| August 31, 2026 | $36.33 |
| July 31, 2026 | $34.02 |
| June 30, 2026 | $32.05 |
| May 29, 2026 | $31.17 |
| April 30, 2026 | $29.82 |
| March 31, 2026 | $30.65 |
| February 27, 2026 | $34.46 |
| January 30, 2026 | $33.65 |
| December 31, 2025 | $32.65 |
| November 28, 2025 | $33.34 |
| November 20, 2025 | $31.91 |
At a glance
The company
Designs, manufactures and sells medical devices for respiratory care, sleep apnea treatment, and surgery in acute and chronic settings
Latest results
Quarter to March 31, 2025 · EPS $0.38 (estimate $0.34)
Next event
TickerLandia's take on Fisher And Paykel Healthcare Corpo
- Pricier than similar companies: trailing 12-month P/E 58 vs 42 (+38%) in a group of 10.
- Strong point: Market momentum (87/100 in its group). Weak point: Earnings stability (47/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.22% from the 52-week high
Analysts · 9 analysts
Average target$39.51−2.25% vs. price
Buy 8 · Hold 0 · Sell 1
TickerLandia Fingerprint: Fisher And Paykel Healthcare Corpo
Compared with similar companies: very strong momentum, very high price, and very high profitability.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high87
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 57.7 78 Forward P/E 45.6 87 EV/EBITDA 30.8 87 Price/book 13.8 96 Price/sales 10.3 87 Profitabilityvery high83
How much it earns on revenue and capital.
Metric Value Position in group ROA 14.7% 87 ROE 23.4% 84 Operating margin 27.6% 84 Gross margin 63.7% 75 Net margin 20.3% 84 Earnings stabilityaverage47
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Margin variabilitycounts in reverse: lower means more earnings stability 4.2% 31 Growthhigh72
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +14.30% 40 Average revenue growth (3 years) +13.44% 87 Revenue growth (year over year) +14.00% 90 Financial strengthvery high82
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.32 66 Debt/equitycounts in reverse: lower means more financial strength 0.07 89 Interest coverage 61.8 88 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.42 83 Dividendaverage57
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 54.2% 73 Dividend yield 1.1% 41 Consecutive dividend years at least 25 years 56 Market momentumvery strong87
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +19.92% 94 1-year return +26.67% 76 Relative strength (3 months) +19.56% 83 Relative strength (6 months) +46.08% 95 Risklow28
How much the price swings.
Metric Value Position in group Volatility (60 days) 18.6% 5 Beta (1 year) 0.82 56 Maximum drawdown (12 months) 23.1% 23
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Fisher And Paykel Healthcare Corpo is pricier than similar companies
Fisher And Paykel Healthcare Corpo's P/E (trailing 12 months): 57.7, +38% against the median of a group of 10 similar companies (41.9).
Compared with 10 similar companies
| Metric | Fisher And Paykel Healthcare Corpo | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 57.7 | Middle | |
| Forward P/E | 45.6 | High | |
| Operating margin | 27.6% | High | |
| ROE | 23.4% | High | |
| Debt/equity | 0.07 | Low |
Grey band: the middle half of the group; tick: the median; dot: Fisher And Paykel Healthcare Corpo. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
1.22B id:5
Latest quarter · Q1 2026
Net income
255.5M id:5
Latest quarter · Q1 2026
Quarterly net margin
20.9%
Latest quarter · Q1 2026
Numbers and valuation
Full valuation- Market cap
- $23.78B
- P/E
- 57.7
- EPS
- $0.70
- Volume
- 561.59K
- Daily trading
- €12.4M
- Dividend yield
- 1.09%
- Last ex-dividend on June 22, 2026
How Fisher And Paykel Healthcare Corpo is changing
All resultsRevenue grew 3.2% a year on average over the last 5 years
Operating margin rose from 21.0% to 27.6%
Profits turn into cash: free cash flow equal to 103% of net income
Returns
Fisher And Paykel Healthcare Corpo returns
$1,000 invested in Fisher And Paykel Healthcare Corpo 5 years ago, on November 22, 2021, would be worth $1,341 today: +34.06% in total, +6.05% per year. This is the price return only: dividends are excluded.
| Period | Fisher And Paykel Healthcare Corpo | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | +1.30% | −2.54% | $1,013 |
| 6 months | +47.73% | +1.13% | $1,477 |
| Year to date | +23.80% | −1.40% | $1,238 |
| 1 year | +26.67% | +0.47% | $1,267 |
| 3 years | +97.56% | +21.74% | $1,976 |
| 5 years | +34.06% | +16.86% | $1,341 |
| 10 years | +386.99% | +60.57% | $4,870 |
Over the last 6 months it has done better than 85% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Fisher And Paykel Healthcare Corpo: technical analysis
Fisher And Paykel Healthcare Corpo is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its all-time closing high.
- Trend
- Upward
- RSI (14 sessions)
- 66
- Between 30 and 70
- vs 200-session average
- +19.92%
Active signals
New 52-week high.
since November 19, 2026
Support and resistance
Price areas where Fisher And Paykel Healthcare Corpo has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$40.42
- Support$36.07−10.75%2 touches, last on November 2, 2026
- Support$34.74−14.06%5 touches, last on September 21, 2026
- Support$33.73−16.55%3 touches, last on July 7, 2026
Volatility and risk
Over the last year it has moved roughly in line with the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 0.82
- Volatility (60 sessions, annualised)
- 18.6%
- Largest fall in the last year
- −23.14%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Fisher And Paykel Healthcare Corpo: seasonality
Average monthly price change over 25 years
Over the last 25 years, the strongest month for Fisher And Paykel Healthcare Corpo has been November: +3.35% on average, positive in 16 years out of 24. The weakest has been January: −1.55% on average, positive in 10 years out of 25.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.55% | −1.47% | 10 of 25 |
| February | −1.10% | +0.68% | 13 of 25 |
| March | +1.01% | +1.45% | 13 of 25 |
| April | −0.04% | 0.00% | 12 of 25 |
| May | +0.59% | 0.00% | 12 of 25 |
| June | +2.37% | +2.10% | 14 of 25 |
| July | +2.06% | +1.37% | 15 of 25 |
| August | +2.31% | +2.53% | 15 of 25 |
| September | +0.95% | +1.32% | 14 of 25 |
| October | +0.88% | +0.56% | 13 of 25 |
| November | +3.35% | +2.45% | 16 of 24 |
| December | +2.96% | +2.20% | 16 of 25 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Fisher And Paykel Healthcare Corpo and its competitors
Based in Auckland, New Zealand, Fisher & Paykel Healthcare has existed since 1934. The company designs, manufactures and sells medical devices for respiratory care and surgery, including high-flow nasal therapy, invasive and noninvasive ventilation, humidification systems and breathing circuits. Its range also covers infant respiratory products and homecare equipment for treating obstructive sleep apnea, such as CPAP devices, masks and data management software. Hospitals and patients at home are served in North America, Europe, Asia Pacific and other international markets.
- Headquarters
- Auckland, New Zealand
- Employees
- 7,357
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Fisher And Paykel Healthcare CorpoFPH | $15.85B | 27.6% | 57.7 | +47.73% |
| Lenskart SolutionsLENSKART | $13.82B | 10.5% | 163.9 | +51.79% |
| Resmed CdiRMD | $33.23B | 34.0% | 22.3 | +21.12% |
| HOYA7741 | $47.84B | 34.4% | 27.3 | −13.64% |
| AnsellANN | $4.31B | 15.0% | 21.6 | +79.76% |
| ColoplastCOLO.B | $16.42B | 25.7% | 36.3 | +20.27% |
Same industry or related industries, similar size. Compare Fisher And Paykel Healthcare Corpo with its competitors · Full profile
More on Fisher And Paykel Healthcare Corpo
- Fisher And Paykel Healthcare Corpo revenue and financials
- Fisher And Paykel Healthcare Corpo dividend and valuation
- Fisher And Paykel Healthcare Corpo stock return
- Fisher And Paykel Healthcare Corpo employees, headquarters and business
